Skip to main content
SpringerLink
Log in

Central Nervous System Involvement in Peripheral T Cell Lymphoma

  • T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease.

Recent Findings

Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2–6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement > 1 has been consistently found to be a risk factor for CNS relapse.

Summary

Currently, there is no consensus about indications for CNS prophylactic treatment. A high-dose systemic methotrexate-based regimen is the most commonly used treatment, with or without consolidation with high-dose chemotherapy with autologous stem cell transplantation for both primary and secondary CNS involvement. This approach, however, is generally toxic for older patients. New therapeutic approaches against PTCL are therefore needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Menon MP, Nicolae A, Meeker H, Raffeld M, Xi L, Jegalian AG, et al. Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol. 2015;39(12):1719–29. https://doi.org/10.1097/PAS.0000000000000503.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ferreri AJ, Blay JY, Reni M, Pasini F, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72. https://doi.org/10.1200/JCO.2003.09.139.

    Article  PubMed  Google Scholar 

  3. Chihara D, Fowler N, Oki Y, Fanale M, et al. Difference in survival outcome of primary central nervous system lymphoma by histologic types. Blood. 2017:Abstract 4137.

  4. Choi JS, Nam DH, Ko YH, Seo JW, Choi YL, Suh YL, et al. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas. Am J Surg Pathol. 2003;27(7):919–28. https://doi.org/10.1097/00000478-200307000-00007.

    Article  PubMed  Google Scholar 

  5. Hayakawa T, Takakura K, Abe H, Yoshimoto T, et al. Primary central nervous system lymphoma in Japan—a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neuro-Oncol. 1994;19(3):197–215.

    Article  CAS  Google Scholar 

  6. Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–24. https://doi.org/10.1111/bjh.14073.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, et al. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244–8. https://doi.org/10.1038/leu.2014.200.

    Article  CAS  PubMed  Google Scholar 

  8. Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460–72. https://doi.org/10.1182/blood-2014-03-559542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233–9. https://doi.org/10.1200/JCO.2005.07.109.

    Article  PubMed  Google Scholar 

  10. •• Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–6. https://doi.org/10.1200/JCO.2012.44.7524. First large study analyzed the survival outcome of relapsed/refractory peripheral T-cell lymphoma.

  11. Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, et al. Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol. 2016;55(5):561–6. https://doi.org/10.3109/0284186X.2015.1118656.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chihara D, Fanale MA, Miranda RN, Noorani M, et al. The risk of central nervous system (CNS) relapses in patients with peripheral T-cell lymphoma. Blood. 2016;128(22):4153.

    Google Scholar 

  13. •• Ellin F, Landstrom J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126(1):36–41. https://doi.org/10.1182/blood-2014-12-616961. Large study using population-based data analyzing the risk factor for central nervous system relapse in peripheral T-cell lymphoma.

  14. Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1636–43. https://doi.org/10.1093/annonc/mdq645.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115(26):5427. https://doi.org/10.1182/blood-2010-02-266890.

    Article  CAS  PubMed  Google Scholar 

  16. Network NCC. T-cell lymphomas 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

  17. Teshima T, Akashi K, Shibuya T, Taniguchi S, Okamura T, Harada M, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer. 1990;65(2):327–32. https://doi.org/10.1002/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W.

    Article  CAS  PubMed  Google Scholar 

  18. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–93. https://doi.org/10.1182/blood-2013-10-530659.

    Article  CAS  PubMed  Google Scholar 

  19. Cheah CY, Seymour JF. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep. 2015;17(6):25.

    Article  PubMed  Google Scholar 

  20. Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5):1267–73. https://doi.org/10.1093/annonc/mdr440.

    Article  CAS  PubMed  Google Scholar 

  21. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944–51. https://doi.org/10.1002/cncr.26588.

    Article  CAS  PubMed  Google Scholar 

  22. Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012;159(1):39–49. https://doi.org/10.1111/j.1365-2141.2012.09247.x.

    Article  CAS  PubMed  Google Scholar 

  23. Bernstein SH, Unger JM, Leblanc M, Friedberg J, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114–9. https://doi.org/10.1200/JCO.2008.16.8021.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Arkenau HT, Chong G, Cunningham D, Watkins D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541–5. https://doi.org/10.1093/annonc/mdl434.

    Article  PubMed  Google Scholar 

  25. Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072–9. https://doi.org/10.1038/bjc.2014.405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Network NCC. Central Nervous System Cancers 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

  27. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–8. https://doi.org/10.1200/JCO.2017.72.7602.

    Article  PubMed  Google Scholar 

  28. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17. https://doi.org/10.1016/0360-3016(92)90538-S.

    Article  CAS  PubMed  Google Scholar 

  29. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21(24):4483–8. https://doi.org/10.1200/JCO.2003.03.108.

    Article  CAS  PubMed  Google Scholar 

  30. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643–8. https://doi.org/10.1200/JCO.2002.11.013.

    Article  PubMed  Google Scholar 

  31. Ferreri AJ, Reni M, Dell’Oro S, Ciceri F, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology. 2001;60(2):134–40. https://doi.org/10.1159/000055310.

    Article  CAS  PubMed  Google Scholar 

  32. O’Brien P, Roos D, Pratt G, Liew K, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18(3):519–26. https://doi.org/10.1200/JCO.2000.18.3.519.

    Article  PubMed  Google Scholar 

  33. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–43. https://doi.org/10.1200/JCO.1992.10.4.635.

    Article  CAS  PubMed  Google Scholar 

  34. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570–4. https://doi.org/10.1200/JCO.2006.06.6910.

    Article  CAS  PubMed  Google Scholar 

  35. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47. https://doi.org/10.1016/S1470-2045(10)70229-1.

    Article  CAS  PubMed  Google Scholar 

  36. Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. https://doi.org/10.1182/blood-2014-10-604561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Morris PG, Correa DD, Yahalom J, Raizer JJ, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9. https://doi.org/10.1200/JCO.2013.50.4910.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38(6):417–20. https://doi.org/10.1038/sj.bmt.1705452.

    Article  CAS  PubMed  Google Scholar 

  39. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151–6. https://doi.org/10.1200/JCO.2003.05.024.

    Article  CAS  PubMed  Google Scholar 

  40. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996;14(2):556–64. https://doi.org/10.1200/JCO.1996.14.2.556.

    Article  CAS  PubMed  Google Scholar 

  41. Schmitz N, Wu HS. Advances In the treatment of secondary CNS lymphoma. J Clin Oncol. 2015;33(33):3851–3. https://doi.org/10.1200/JCO.2015.63.1143.

    Article  CAS  PubMed  Google Scholar 

  42. Korfel A, Elter T, Thiel E, Hanel M, Mohle R, Schroers R, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–70. https://doi.org/10.3324/haematol.2012.077917.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ferreri AJ, Donadoni G, Cabras MG, Patti C, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–10. https://doi.org/10.1200/JCO.2015.61.1236.

    Article  PubMed  Google Scholar 

  44. Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–63. https://doi.org/10.1200/JCO.2015.64.9897.

    Article  CAS  PubMed  Google Scholar 

  45. Grommes C, Pastore A, Gavrilovic I, Kaley T, et al. Single-agent ibrutinib in recurrent/refractory central nervous system lymphoma. Blood. 2016;128(22):783.

    Google Scholar 

  46. Ghesquieres H, Houillier C, Chinot O, Choquet S, et al. Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC Network. Blood. 2016;128(22):785.

    Google Scholar 

  47. Choquet S, Houillier C, Bijou F, Houot R, et al. Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC Network. Blood. 2016;128(22):784.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, MSC10 55501, The University of New Mexico, Albuquerque, NM, 87131, USA

    Dai Chihara

  2. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Yasuhiro Oki

Authors
  1. Dai Chihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhiro Oki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dai Chihara.

Ethics declarations

Conflict of Interest

Dai Chihara and Yasuhiro Oki each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Topical Collection on T-Cell and Other Lymphoproliferative Malignancies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chihara, D., Oki, Y. Central Nervous System Involvement in Peripheral T Cell Lymphoma. Curr Hematol Malig Rep 13, 1–6 (2018). https://doi.org/10.1007/s11899-018-0431-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-018-0431-4

Keywords

Search

Navigation